Paper Summary:

Title: Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC

Author(s): Zhou, Caicun (author);Wang, Ziping (author);Sun, Meili (author);Cao, Lejie (author);Ma, Zhiyong (author);Wu, Rong (author);Yu, Yan (author);Yao, Wenxiu (author);Sun, Si (author);Chen, Jianhua (author);Zhuang, Wu (author);Cui, Jiuwei (author);Chen, Xueqin (author);Lu, You (author);Shen, Hong (author);Hu, Chunhong (author);Liu, Jiwei (author);Liu, Yunpeng (author);Wang, Mengzhao (author);Li, Xingya (author);Sun, Ping (author);Shu, Yongqian (author);Zhou, Jianying (author);Li, Jingzhang (author);Gu, Kangsheng (author);Wang, Changli (author);Zhao, Hui (author);Zhang, Yiping (author);Liu, Chunling (author);Wang, Jingru (author);Chen, Rumei (author);Qin, Mengmeng (author);Wang, Hao (author);Yang, Jason (author)

Year: 2023

DOI: 10.1038/s43018-023-00578-z

URL: https://doi.org/10.1038/s43018-023-00578-z

Download Paper from Sci-Hub:

• https://sci-hub.su/10.1038/s43018-023-00578-z
• https://sci-hub.st/10.1038/s43018-023-00578-z
• https://sci-hub.box/10.1038/s43018-023-00578-z
• https://sci-hub.ru/10.1038/s43018-023-00578-z
• https://sci-hub.red/10.1038/s43018-023-00578-z

Generate Citation